Del-desiran, the lead muscle-disease therapy Novartis bought with Avidity for $12 billion, missed its main goal in myotonic dystrophy — sending the stock to its worst day since 2020.
A 15,000-person Swedish study found people with bipolar disorder taking semaglutide had a 21% lower risk of psychiatric hospitalization — an intriguing signal, but not proof, and not seen with every GLP-1 drug.
A pack-level barcode tells you the box is genuine. It does not tell you the nurse is holding the right vial for the right patient. European industry and hospital pharmacists now want a code on every dose by 2031.
Modulator drugs fix the CFTR protein after the cell has built it wrong. ACT-101 is an inhaled RNA drug that aims to act before the protein exists at all — if it can be turned into a stable aerosol.
Radiopharmaceuticals decay while you ship them, so you cannot build inventory. That is why a $160M plant in Hamilton counts as strategic infrastructure rather than just another factory.
The drug did exactly what it was designed to do — free IL-6 and hsCRP fell. Cardiovascular events did not. After ZEUS missed, two more Phase 3 trials were stopped for futility.
Higher blood tyrosine tracked with about a year of lost life expectancy in men and nothing in women. The researchers never tested a supplement — and say plainly that their results do not show supplements shorten life.
Dormant tumour cells are the reason breast cancer can return a decade later. Mapping where they sit inside tumours shows them surrounded by specific immune and support cells — a hiding place that might itself be a drug target.
Both arms of this trial got lifestyle advice. Only one got coaching, supervision and 38 group meetings — and that arm improved 55% more on global cognition. The finding is about delivery, not ingredients.
£500,000 each is seed money, not a war chest. What these two UK biotechs are really being given is translational infrastructure — the thing that usually kills academic science before it becomes a drug.
Three lots of hospital bulk epinephrine were pulled after vials cracked and leaked, with nylon, acrylic, polyethylene and glass particles found inside. No injuries have been reported — which is not the same as none having occurred.
Ten daily doses of an approved leukaemia drug, given as antiretroviral therapy started, cut the intact viral reservoir in macaques — and it stayed down for months after the drug stopped.